Clinical phenotypes, autoimmunity and outcomes in Rosai–Dorfman disease: An international multicentre cohort study
British Journal of Haematology · 11.11.2026
DOI: 10.1111/bjh.70939 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift British Journal of Haematology, online erschienen am 11.11.2026. Verfasst von Mitali Sen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA. Die Arbeit nennt 13 Literaturangaben. Gefördert von: American Cancer Society.
Abstract (Originalsprache)
Rosai–Dorfman disease (RDD) is a rare histiocytic neoplasm with diverse clinical behaviour and immune abnormalities with unknown clinical significance. We performed a retrospective cohort study of 162 patients with RDD from 2003 to 2025 at five international referral centres. Median age was 48 years and 64.8% were female. Multisystem disease occurred in 87 patients (53.7%), commonly involving skin/subcutaneous tissue (49.4%), lymph nodes (39.5%) and bones (34%). Molecular testing was available for 102 patients; 40 (39.2%) were mitogen‐activated protein kinase/rat sarcoma virus oncogene homolog signaling pathway (MAPK/RAS)‐altered, commonly with kirsten rat sarcoma viral oncogene homolog ( KRAS ) or mitogen‐activated protein kinase 1 ( MAP2K/MEK ) alterations. MAPK/RAS alterations were associated with multisystem disease ( p = 0.0034). Autoimmune disease (AID) was documented in 29 patients (17.9%), usually preceding RDD, and 45/95 patients (47.4%) with available autoantibody status had at least one positive autoantibody. Among 153 patients with response data, objective response occurred in 94 (61.4%). Response distribution differed by disease extent; single‐system disease was associated with more complete responses and less progression than multisystem disease. At a median follow‐up of 2.49 years, eight deaths occurred; 5‐year overall survival was 93.4%. AID and autoantibody positivity were not associated with response or overall survival. These findings support disease extent and molecular status as clinically relevant dimensions of RDD assessment, while autoimmune and serological abnormalities should be interpreted in clinical context.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- HealthPartners Frauenshuh Cancer Center, St Louis Park, Minnesota, USA.
- Division of Hematology and Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
- Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Mitali Sen, Gordon J Ruan, Samuel B Reynolds, Haadi Ali, Diana Morlote, Matthew J Koster, Jithma P Abeykoon, Hind Salama, Asra Z Ahmed, Ronald S Go, Gaurav Goyal
Förderung
- American Cancer Society
Zitieren
APA
Sen, M., Ruan, G. J., Reynolds, S. B., Ali, H., Yang, X., Morlote, D., Ravindran, A., Shea, L., Koster, M. J., Abeykoon, J. P., Salama, H., Cao, X. X., Ahmed, A. Z., Go, R. S., & Goyal, G. (2026). Clinical phenotypes, autoimmunity and outcomes in Rosai–Dorfman disease: An international multicentre cohort study. British Journal of Haematology. https://doi.org/10.1111/bjh.70939
Vancouver
Sen M, Ruan GJ, Reynolds SB, Ali H, Yang X, Morlote D, et al. Clinical phenotypes, autoimmunity and outcomes in Rosai–Dorfman disease: An international multicentre cohort study. British Journal of Haematology. 2026. doi:10.1111/bjh.70939
BibTeX
@article{Sen2026,
author = {Sen, Mitali and Ruan, Gordon J and Reynolds, Samuel B and Ali, Haadi and Yang, Xi and Morlote, Diana and Ravindran, Aishwarya and Shea, Lauren and Koster, Matthew J and Abeykoon, Jithma P and Salama, Hind and Cao, Xin-Xin and Ahmed, Asra Z and Go, Ronald S and Goyal, Gaurav},
title = {Clinical phenotypes, autoimmunity and outcomes in Rosai–Dorfman disease: An international multicentre cohort study},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70939}
}
EUVIMED